Brief: Enveric Biosciences Receives Notice Of Allowance From USPTO For Development Of C4-Carbonothioate-Substituted Tryptamine Derivatives For Novel Prodrug Of Psilocin
31/10/2023 12:09
Oct 31 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES RECEIVES NOTICE OF ALLOWANCE FROM
USPTO FOR
DEVELOPMENT OF C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE
DERIVATIVES FOR NOVEL PRODRUG OF PSILOCIN
Source text for Eikon: ID:nBwVHPVwa
Further company coverage: ENVB.O
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003